This could be a key observation because it is estimated that Kras mutations are present in approximately 30% of human cancers where GSK3 activity is a requirement for the survival and proliferation of Kras-dependent tumors [79], as GSK3α is the link between Kras promotion of NF-κB pathway activity and the promotion of cancer cell viability. Here, KRAS is linked to cancer.